

K R M L T A - LAB TEST REFERENCE VALUES

| | | |
|----|--|--|
| 1 | 1,25-Dihydroxyvitamin D (1,25-dihydroxycholecalciferol), | See Vitamin D metabolites |
| 2 | 17-Hydroxyprogesterone, serum | |
| 3 | 17-Hydroxyprogesterone Female, follicular | <80 ng/dL |
| 4 | 17-Hydroxyprogesterone Female, luteal | <285 ng/dL |
| 5 | 17-Hydroxyprogesterone Female, postmenopausal | <51 ng/dL |
| 6 | 17-Hydroxyprogesterone Male (adult) | <220 ng/dL |
| 7 | 25-Hydroxyvitamin D (25-Hydroxycholecalciferol), serum | See Vitamin D metabolites |
| 8 | 5-Hydroxyindoleacetic acid, urine | 2–9 mg/24 hr |
| 9 | 6-Thioguanine, whole blood | 230–400 pmol/8x10 ⁸ RBCs |
| 10 | Absolute neutrophil count (ANC) | 2000–8250/ μ L |
| 11 | Acid phosphatase, serum | |
| 12 | Acid phosphatase Total | 0.5–2.0 (Bodansky) units/mL |
| 13 | Acid phosphatase Prostatic fraction | 0.1–0.4 unit/mL |
| 14 | ACTH, plasma | 10–60 pg/mL |
| 15 | Activated partial thromboplastin time | 25–35 seconds |
| 16 | ADAMTS13 activity | >60% |
| 17 | Adrenocorticotrophic hormone (ACTH), plasma | 10–60 pg/mL |
| 18 | Albumin, serum | 3.5–5.5 g/dL |
| 19 | Albumin, urine | <25 mg/24 hr |
| 20 | Albumin-to-creatinine ratio, urine | <30 mg/g |
| 21 | Aldolase, serum | 0.8–3.0 IU/mL |
| 22 | Aldosterone, plasma | |
| 23 | Supine or seated | \leq 10 ng/dL |
| 24 | Standing | <21 ng/dL |
| 25 | Low-sodium diet (supine) | \leq 30 ng/dL |
| 26 | Aldosterone, urine | 5–19 μ g/24 hr |
| 27 | Alkaline phosphatase, serum | 30–120 U/L |
| 28 | Alkaline phosphatase, bone specific | 5.6–18.0 μ g/L for premenopausal women |
| 29 | Alpha ₁ -antitrypsin (AAT), serum | 150–350 mg/dL |
| 30 | Alpha ₂ -antiplasmin activity, plasma | 75%–115% |
| 31 | Alpha-amino nitrogen, urine | 100–290 mg/24 hr |
| 32 | Alpha-fetoprotein, serum | <10 ng/mL |
| 33 | Amino acids, urine | 200–400 mg/24 hr |
| 34 | Aminotransferase, serum alanine (ALT, SGPT) | 10–40 U/L |
| 35 | Aminotransferase, serum aspartate (AST, SGOT) | 10–40 U/L |
| 36 | Ammonia, blood | 40–70 μ g/dL |
| 37 | Amylase, serum | 25–125 U/L (80–180 [Somogyi] units/dL) |
| 38 | Amylase, urine | 1–17 U/hr |
| 39 | Androstenedione, serum | Female: 30–200 ng/dL; male: 40–150 ng/dL |
| 40 | Angiotensin-converting enzyme, serum | 8–53 U/L |
| 41 | Anion gap, serum | 7–13 mEq/L |
| 42 | Antibodies to double-stranded DNA | 0–7 IU/mL |
| 43 | 1,25-Dihydroxyvitamin D (1,25-dihydroxycholecalciferol), | See Vitamin D metabolites |
| 44 | 17-Hydroxyprogesterone, serum | |
| 45 | 17-Hydroxyprogesterone Female, follicular | <80 ng/dL |

| | | |
|----|---|--|
| 46 | 17-Hydroxyprogesterone Female, luteal | <285 ng/dL |
| 47 | 17-Hydroxyprogesterone Female, postmenopausal | <51 ng/dL |
| 48 | 17-Hydroxyprogesterone Male (adult) | <220 ng/dL |
| 49 | 25-Hydroxyvitamin D (25-Hydroxycholecalciferol), serum | See Vitamin D metabolites |
| 50 | 5-Hydroxyindoleacetic acid, urine | 2–9 mg/24 hr |
| 51 | 6-Thioguanine, whole blood | 230–400 pmol/8x10 ⁸ RBCs |
| 52 | Absolute neutrophil count (ANC) | 2000–8250/ μ L |
| 53 | Acid phosphatase, serum | |
| 54 | Acid phosphatase Total | 0.5–2.0 (Bodansky) units/mL |
| 55 | Acid phosphatase Prostatic fraction | 0.1–0.4 unit/mL |
| 56 | ACTH, plasma | 10–60 pg/mL |
| 57 | Activated partial thromboplastin time | 25–35 seconds |
| 58 | ADAMTS13 activity | >60% |
| 59 | Adrenocorticotrophic hormone (ACTH), plasma | 10–60 pg/mL |
| 60 | Albumin, serum | 3.5–5.5 g/dL |
| 61 | Albumin, urine | <25 mg/24 hr |
| 62 | Albumin-to-creatinine ratio, urine | <30 mg/g |
| 63 | Aldolase, serum | 0.8–3.0 IU/mL |
| 64 | Aldosterone, plasma | |
| 65 | Supine or seated | \leq 10 ng/dL |
| 66 | Standing | <21 ng/dL |
| 67 | Low-sodium diet (supine) | \leq 30 ng/dL |
| 68 | Aldosterone, urine | 5–19 μ g/24 hr |
| 69 | Alkaline phosphatase, serum | 30–120 U/L |
| 70 | Alkaline phosphatase, bone specific | 5.6–18.0 μ g/L for premenopausal women |
| 71 | Alpha ₁ -antitrypsin (AAT), serum | 150–350 mg/dL |
| 72 | Alpha ₂ -antiplasmin activity, plasma | 75%–115% |
| 73 | Alpha-amino nitrogen, urine | 100–290 mg/24 hr |
| 74 | Alpha-fetoprotein, serum | <10 ng/mL |
| 75 | Amino acids, urine | 200–400 mg/24 hr |
| 76 | Aminotransferase, serum alanine (ALT, SGPT) | 10–40 U/L |
| 77 | Aminotransferase, serum aspartate (AST, SGOT) | 10–40 U/L |
| 78 | Ammonia, blood | 40–70 μ g/dL |
| 79 | Amylase, serum | 25–125 U/L (80–180 [Somogyi] units/dL) |
| 80 | Amylase, urine | 1–17 U/hr |
| 81 | Androstenedione, serum | Female: 30–200 ng/dL; male: 40–150 ng/dL |
| 82 | Angiotensin-converting enzyme, serum | 8–53 U/L |
| 83 | Anion gap, serum | 7–13 mEq/L |
| 84 | Antibodies to double-stranded DNA | 0–7 IU/mL |
| 85 | Anticardiolipin antibodies | |
| 86 | Anticardiolipin IgG | <20 GPL |
| 87 | Anticardiolipin IgM | <20 MPL |
| 88 | Anti-cyclic citrullinated peptide (ACCP), antibodies to | <20 units |
| 89 | Antideoxyribonuclease B | <280 units |
| 90 | Anti-F-actin antibodies, serum | \leq 1:80 |
| 91 | Antihistone antibodies | <1:16 |
| 92 | Anti-liver-kidney microsomal antibodies (anti-LKM) | <1:20 |

| | | |
|-----|--|---|
| 93 | Antimitochondrial antibodies | ≤1:5 |
| 94 | Anti-myelin associated glycoprotein antibody | <1:1600 |
| 95 | Antimyeloperoxidase antibodies | <1.0 U |
| 96 | Antinuclear antibodies | ≤1:40 |
| 97 | Anti-smooth muscle antibodies | ≤1:80 |
| 98 | Antistreptolysin O titer | <200 Todd units |
| 99 | Antithrombin activity | 80%–120% |
| 100 | Antithyroglobulin antibodies | <20 U/mL |
| 101 | Antithyroid peroxidase antibodies | <2.0 U/mL |
| 102 | Anti-tissue transglutaminase antibodies | See Tissue transglutaminase antibody |
| 103 | Arterial blood gas studies (patient breathing room air): | |
| 104 | pH | 7.38–7.44 |
| 105 | PaCO ₂ | 38–42 mm Hg |
| 106 | PaO ₂ | 75–100 mm Hg |
| 107 | Bicarbonate | 23–26 mEq/L |
| 108 | Oxygen saturation | ≥95% |
| 109 | Methemoglobin | 0.5%–3.0% |
| 110 | Ascorbic acid (vitamin C), blood | 0.4–1.5 mg/dL |
| 111 | Ascorbic acid, leukocyte | 16.5 ± 5.1 mg/dL of leukocytes |
| 112 | (1,3)-Beta-D-glucan, serum | <60 pg/mL |
| 113 | Beta-human chorionic gonadotropin (beta-hCG), serum | Female, premenopausal nonpregnant: |
| 114 | Beta-human chorionic gonadotropin (beta-hCG), urine | <2 mIU/24 hr |
| 115 | Beta ₂ -glycoprotein I antibodies: | |
| 116 | Beta ₂ -glycoprotein I IgG | <21 SGU |
| 117 | Beta ₂ -glycoprotein I IgM | <21 SMU |
| 118 | Beta-hydroxybutyrate, serum | <0.4 mmol/L |
| 119 | Beta ₂ -microglobulin, serum | 0.54–2.75 mg/L |
| 120 | Bicarbonate, serum | 23–28 mEq/L |
| 121 | Bilirubin, serum | |
| 122 | Total | 0.3–1.0 mg/dL |
| 123 | Direct | 0.1–0.3 mg/dL |
| 124 | Indirect | 0.2–0.7 mg/dL |
| 125 | Bleeding time (template) | <8 minutes |
| 126 | Blood urea nitrogen (BUN), serum or plasma | 8–20 mg/dL |
| 127 | B-type natriuretic peptide, plasma | <100 pg/mL |
| 128 | C peptide, serum | 0.8–3.1 ng/mL |
| 129 | Calcitonin, serum | Female: ≤5 pg/mL; male: ≤10 pg/mL |
| 130 | Calcium, ionized, serum | 1.12–1.23 mmol/L |
| 131 | Calcium, serum | 8.6–10.2 mg/dL |
| 132 | Calcium, urine | Female: <250 mg/24 hr; male: <300 mg/24 |
| 133 | Carbohydrate antigens, serum | |
| 134 | CA 19-9 | 0–37 U/mL |
| 135 | CA 27-29 | <38.0 U/mL |
| 136 | CA 125 | <35 U/mL |
| 137 | Carbon dioxide content, serum | 23–30 mEq/L |
| 138 | Carboxyhemoglobin, blood | <5% |
| 139 | Carcinoembryonic antigen, plasma | <2.5 ng/mL |

| | | |
|-----|--|---------------------------------------|
| 140 | Carotene, serum | 75–300 µg/dL |
| 141 | Catecholamines, plasma | |
| 142 | Dopamine | <30 pg/mL |
| 143 | Epinephrine | |
| 144 | Supine | <50 pg/mL |
| 145 | Standing | <95 pg/mL |
| 146 | Norepinephrine | |
| 147 | Supine | 112–658 pg/mL |
| 148 | Standing | 217–1109 pg/mL |
| 149 | Catecholamines, urine | |
| 150 | Dopamine | 65–400 µg/24 hr |
| 151 | Epinephrine | 2–24 µg/24 hr |
| 152 | Norepinephrine | 15–100 µg/24 hr |
| 153 | Total | 26–121 µg/24 hr |
| 154 | CD4 T-lymphocyte count | 530–1570/µL |
| 155 | Cell count, CSF: | |
| 156 | Leukocytes (WBCs) | 0–5 cells/µL |
| 157 | Erythrocytes (RBCs) | 0/µL |
| 158 | Ceruloplasmin, serum (plasma) | 25–43 mg/dL |
| 159 | Chloride, CSF | 120–130 mEq/L |
| 160 | Chloride, serum | 98–106 mEq/L |
| 161 | Chloride, urine | |
| 162 | Spot | mEq/L; varies |
| 163 | 24-hour measurement | mEq/24 hr; varies with intake |
| 164 | Cholesterol, serum | |
| 165 | Cholesterol Total | |
| 166 | Cholesterol Desirable | <200 mg/dL |
| 167 | Borderline-high | 200–239 mg/dL |
| 168 | Cholesterol High | >239 mg/dL |
| 169 | High-density lipoprotein (HDL) | |
| 170 | HDL Low | Female: <50 mg/dL; male: <40 mg/dL |
| 171 | Low-density lipoprotein (LDL) | |
| 172 | LDL Optimal | <100 mg/dL |
| 173 | LDL Near-optimal | 100–129 mg/dL |
| 174 | LDL Borderline-high | 130–159 mg/dL |
| 175 | LDL High | 160–189 mg/dL |
| 176 | LDL Very high | >189 mg/dL |
| 177 | Cholinesterase, serum (pseudocholinesterase) | ≥0.5 pH units/hr |
| 178 | Packed cells | ≥0.7 pH units/hr |
| 179 | Chorionic gonadotropin, beta-human (beta-hCG), serum | See Beta-human chorionic gonadotropin |
| 180 | Chorionic gonadotropin, beta-human (beta-hCG), urine | See Beta-human chorionic gonadotropin |
| 181 | Chromogranin A, serum | <93 ng/mL |
| 182 | Citrate, urine | 250–1000 mg/24 hr |
| 183 | Clotting time (Lee-White) | 5–15 minutes |
| 184 | Coagulation factors, plasma | |
| 185 | Factor I (fibrinogen) | 200–400 mg/dL |
| 186 | Factor II (prothrombin) | 60%–130% |

| | | |
|-----|---|--|
| 187 | Factor V (accelerator globulin) | 60%–130% |
| 188 | Factor VII (proconvertin) | 60%–130% |
| 189 | Factor VIII (antihemophilic globulin) | 50%–150% |
| 190 | Factor IX (plasma thromboplastin component) | 60%–130% |
| 191 | Factor X (Stuart factor) | 60%–130% |
| 192 | Factor XI (plasma thromboplastin antecedent) | 60%–130% |
| 193 | Factor XII (Hageman factor) | 60%–130% |
| 194 | Factor XIII | 57%–192% |
| 195 | Cold agglutinin titer | >1:64 positive |
| 196 | Complement components, serum | |
| 197 | C3 | 100–233 mg/dL |
| 198 | C4 | 14–48 mg/dL |
| 199 | CH50 | 110–190 units/mL |
| 200 | Copper, serum | 100–200 µg/dL |
| 201 | Copper, urine | 0–100 µg/24 hr |
| 202 | Coproporphyrin, urine | 50–250 µg/24 hr |
| 203 | Cortisol, free, urine | 4–50 µg/24 hr |
| 204 | Cortisol, plasma | |
| 205 | 8:00 AM | 5–25 µg/dL |
| 206 | 4:00 PM | <10 µg/dL |
| 207 | 1 hour after cosyntropin | ≥18 µg/dL |
| 208 | Overnight suppression test (1-mg) | <1.8 µg/dL |
| 209 | Overnight suppression test (8-mg) | >50% reduction in cortisol |
| 210 | Cortisol, saliva, 11 PM – midnight | <0.09 µg/dL |
| 211 | C-reactive protein, serum | ≤0.8 mg/dL |
| 212 | C-reactive protein (high sensitivity), serum | Low risk = <1.0 mg/L; Average risk = |
| 213 | Creatine kinase, serum | |
| 214 | Total | Female: 30–135 U/L; male: 55–170 U/L |
| 215 | MB isoenzymes | <5% of total |
| 216 | Creatine, urine | Female: 0–100 mg/24 hr; male: 0–40 mg/24 |
| 217 | Creatinine clearance, urine | 90–140 mL/min/1.73 m ² |
| 218 | Creatinine, serum | Female: 0.50–1.10 mg/dL; male: 0.70–1.30 |
| 219 | Creatinine, urine | |
| 220 | Spot | mg/dL; varies |
| 221 | 24-hour measurement | 15–25 mg/kg body weight/24 hr |
| 222 | Cyclosporine, whole blood (trough) | |
| 223 | Therapeutic | 100–200 ng/mL |
| 224 | 0–3 months post transplantation | 150–250 ng/mL |
| 225 | More than 3 months post transplantation | 75–125 ng/mL |
| 226 | D-dimer, plasma | <0.5 µg/mL |
| 227 | Dehydroepiandrosterone sulfate (DHEA-S), serum | Female: 44–332 µg/dL; male: 89–457 µg/dL |
| 228 | Delta-aminolevulinic acid, serum | <20 µg/dL |
| 229 | Digoxin, serum | Therapeutic: 1.0–2.0 ng/mL (<1.2 ng/mL |
| 230 | Dihydrotestosterone, serum | Adult male: 25–80 ng/dL |
| 231 | Dopamine, plasma | <30 pg/mL |
| 232 | Dopamine, urine | 65–400 µg/24 hr |
| 233 | D-Xylose absorption (after ingestion of 25 g of D-xylose) | |

| | | |
|-----|---|--------------------------------------|
| 234 | Serum | 25–40 mg/dL |
| 235 | Urinary excretion | 4.5–7.5 g during a 5-hr period |
| 236 | Electrolytes, serum | |
| 237 | Sodium | 136–145 mEq/L |
| 238 | Potassium | 3.5–5.0 mEq/L |
| 239 | Chloride | 98–106 mEq/L |
| 240 | Bicarbonate | 23–28 mEq/L |
| 241 | Epinephrine, plasma | |
| 242 | Supine | <110 pg/mL |
| 243 | Standing | <140 pg/mL |
| 244 | Epinephrine, urine | <20 µg/24 hr |
| 245 | Erythrocyte count | 4.2–5.9 million/µL |
| 246 | Erythrocyte sedimentation rate (Westergren) | Female: 0–20 mm/hr; male: 0–15 mm/hr |
| 247 | Erythrocyte survival rate (⁵¹ Cr) | T _{1/2} = 28 days |
| 248 | Erythropoietin, serum | 4–26 mU/mL |
| 249 | Estradiol, serum | |
| 250 | Estradiol Female, follicular | 10–180 pg/mL |
| 251 | Estradiol Mid-cycle peak | 100–300 pg/mL |
| 252 | Estradiol Luteal | 40–200 pg/mL |
| 253 | Estradiol Postmenopausal | <10 pg/mL |
| 254 | Estradiol Male | 20–50 pg/mL |
| 255 | Estriol, urine | >12 mg/24 hr |
| 256 | Estrogen receptor protein | Negative: <10 fmol/mg protein |
| 257 | Estrone, serum | 10–60 pg/mL |
| 258 | Ethanol, blood | <0.005% (<5 mg/dL) |
| 259 | Coma level | >0.5% (>500 mg/dL) |
| 260 | Intoxication | ≥0.08%–0.1% (≥80–100 mg/dL) |
| 261 | Euglobulin clot lysis time | 2–4 hours at 37.0 C |
| 262 | Everolimus, whole blood (trough) | Therapeutic: 3.0–8.0 ng/mL |
| 263 | Factor XIII, B subunit, plasma | 60–130 U/dL |
| 264 | Fecal (Stool) fat | <7 g/24 hr |
| 265 | Fecal (Stool) nitrogen | <2 g/24 hr |
| 266 | Fecal (Stool) pH | 7.0–7.5 |
| 267 | Fecal (Stool) potassium | <10 mEq/L |
| 268 | Fecal (Stool) sodium | <10 mEq/L |
| 269 | Fecal (Stool) urobilinogen | 40–280 mg/24 hr |
| 270 | Fecal (Stool) weight | <250 g/24 hr |
| 271 | Ferritin, serum | Female: 11–307 ng/mL; male: 24–336 |
| 272 | Fibrin(ogen) degradation products | <10 µg/mL |
| 273 | Fibrinogen, plasma | 200–400 mg/dL |
| 274 | Fibroblast growth factor-23, serum | 30–80 RU/mL |
| 275 | Flecainide, serum | Therapeutic: 0.2–1.0 µg/mL |
| 276 | Folate, red cell | 150–450 ng/mL of packed cells |
| 277 | Folate, serum | 1.8–9.0 ng/mL |
| 278 | Follicle-stimulating hormone, serum | |
| 279 | Female, follicular/luteal | 2–9 mIU/mL (2–9 U/L) |
| 280 | Female, mid-cycle peak | 4–22 mIU/mL (4–22 U/L) |

| | | |
|-----|--|--|
| 281 | Female, postmenopausal | >30 mIU/mL (>30 U/L) |
| 282 | Male (adult) | 1–7 mIU/mL (1–7 U/L) |
| 283 | Children, Tanner stages 1, 2 | 0.5–8.0 mIU/mL (0.5–8.0 U/L) |
| 284 | Children, Tanner stages 3, 4, 5 | 1–12 mIU/mL (1–12 U/L) |
| 285 | Free kappa light chain, serum | 3.3–19.4 mg/L |
| 286 | Free kappa-to-free lambda light chain ratio, serum | 0.26–1.65 |
| 287 | Free lambda light chain, serum | 5.7–26.3 mg/L |
| 288 | Fructosamine, serum | 175–280 mmol/L |
| 289 | Gamma globulin, CSF | 6.1–8.3 mg/dL |
| 290 | Gamma-glutamyl transpeptidase, serum | Female: 8–40 U/L; male: 9–50 U/L |
| 291 | Gastric secretion | |
| 292 | Basal acid analysis | 10–30 units of free acid |
| 293 | Basal acid output | Female: 2.0 ± 1.8 mEq of HCl/hr; male: 3.0 |
| 294 | Maximal output after pentagastrin stimulation | 23 ± 5 mEq of HCl/hr |
| 295 | Gastrin, serum | <100 pg/mL |
| 296 | Gentamicin, serum | Therapeutic: peak 5.0–10.0 µg/mL; trough: |
| 297 | Glucose, CSF | 50–75 mg/dL |
| 298 | Glucose, plasma (fasting) | 70–99 mg/dL |
| 299 | Glucose-6-phosphate dehydrogenase, blood | 5–15 units/g of hemoglobin |
| 300 | Glycoprotein α-subunit, serum | <1 ng/mL |
| 301 | Growth hormone, serum | |
| 302 | At rest | <5 ng/mL |
| 303 | Response to provocative stimuli | >7 ng/mL |
| 304 | Haptoglobin, serum | 83–267 mg/dL |
| 305 | Hematocrit, blood | Female: 37%–47%; male: 42%–50% |
| 306 | Hemoglobin A1C | 4.0%–5.6% |
| 307 | Hemoglobin, blood | Female: 12–16 g/dL; male: 14–18 g/dL |
| 308 | Hemoglobin fractionation | |
| 309 | Hb A | 96%–98% |
| 310 | Hb A2 | 1.5%–3.5% |
| 311 | Hb F | <1% |
| 312 | Hemoglobin, plasma | <5.0 mg/dL |
| 313 | Heparin–anti-factor Xa assay, plasma | 0.3–0.7 IU/mL [therapeutic range for |
| 314 | Heparin–platelet factor 4 antibody, serum | Positive: >0.4 optical density units |
| 315 | Hepatic copper | 25–40 µg/g dry weight |
| 316 | Hepatic iron index | <1.0 |
| 317 | Histamine excretion, urine | 20–50 µg/24 hr |
| 318 | Homocysteine, plasma | 5–15 µmol/L |
| 319 | β-Human chorionic gonadotropin (β-hCG), serum | Female, premenopausal nonpregnant: |
| 320 | β-Human chorionic gonadotropin (β-hCG), urine | <2 mIU/24 hr |
| 321 | Hydroxyproline, urine | 10–30 mg/sq meter of body surface/24 hr |
| 322 | Immature platelet fraction | 1%–5% of platelet count |
| 323 | Immune complexes, serum | 0–50 µg/dL |
| 324 | Immunoglobulins, serum | |
| 325 | IgA | 90–325 mg/dL |
| 326 | IgE | <380 IU/mL |
| 327 | IgG | 800–1500 mg/dL |

| | | |
|-----|---|---------------------------------------|
| 328 | IgM | 45–150 mg/dL |
| 329 | Immunoglobulin free light chains, serum | |
| 330 | Kappa | 3.3–19.4 mg/L |
| 331 | Lambda | 5.7–26.3 mg/L |
| 332 | Kappa-to-lambda ratio | 0.26–1.65 |
| 333 | Insulin, serum (fasting) | <20 µU/mL |
| 334 | Insulin-like growth factor 1 (IGF-1) (somatomedin-C), serum | |
| 335 | Ages 16–24 | 182–780 ng/mL |
| 336 | Ages 25–39 | 114–492 ng/mL |
| 337 | Ages 40–54 | 90–360 ng/mL |
| 338 | Ages 55 and older | 71–290 ng/mL |
| 339 | Iodine, urine | |
| 340 | Spot | µg/L; varies |
| 341 | Iron, serum | 50–150 µg/dL |
| 342 | Iron-binding capacity, serum (total) | 250–310 µg/dL |
| 343 | Lactate dehydrogenase, serum | 80–225 U/L |
| 344 | Lactate, arterial blood | <1.3 mmol/L (<1.3 mEq/L) |
| 345 | Lactate, serum or plasma | 0.7–2.1 mmol/L |
| 346 | Lactate, venous blood | 0.7–1.8 mEq/L; 6–16 mg/dL |
| 347 | Lactic acid, serum | 6–19 mg/dL (0.7–2.1 mmol/L) |
| 348 | Lactose tolerance test, GI | Increase in plasma glucose: >15 mg/dL |
| 349 | Lead, blood | 15–40 µg/dL |
| 350 | Lead, urine | <80 µg/24 hr |
| 351 | Leukocyte count | 4000–11,000/µL |
| 352 | Segmented neutrophils | 50%–70% |
| 353 | Band forms | 0%–5% |
| 354 | Lymphocytes | 30%–45% |
| 355 | Monocytes | 0%–6% |
| 356 | Basophils | 0%–1% |
| 357 | Eosinophils | 0%–3% |
| 358 | Lipase, serum | 10–140 U/L |
| 359 | Lipoprotein(a), serum | Desirable: <30 mg/dL |
| 360 | Lithium, plasma | |
| 361 | Lithium Therapeutic | 0.6–1.2 mEq/L |
| 362 | Lithium Toxic level | >2 mEq/L |
| 363 | Luteinizing hormone (LH), serum | |
| 364 | Luteinizing hormone (LH) Female, follicular/luteal | 1–12 mIU/mL (1–12 U/L) |
| 365 | Luteinizing hormone (LH) Female, mid-cycle peak | 9–80 mIU/mL (9–80 U/L) |
| 366 | Luteinizing hormone (LH) Female, postmenopausal | >30 mIU/mL (>30 U/L) |
| 367 | Luteinizing hormone (LH) Male (adult) | 2–9 mIU/mL (2–9 U/L) |
| 368 | Children, Tanner stages 1, 2, 3 | <9.0 mIU/mL (<9.0 U/L) |
| 369 | Children, Tanner stages 4, 5 | 1–15 mIU/mL (1–15 U/L) |
| 370 | lymphocyte subsets | |
| 371 | CD3 | 900–3245/µL |
| 372 | CD4 | 530–1570/µL |
| 373 | CD8 | 430–1060/µL |
| 374 | CD19 CD56 | 208–590/µL 40–500/µL |

| | | |
|-----|--|--|
| 375 | Magnesium, serum | 1.6–2.6 mEq/L |
| 376 | Magnesium, urine | 14–290 mg/24 hr |
| 377 | Mean corpuscular hemoglobin | 28–32 pg |
| 378 | Mean corpuscular hemoglobin concentration | 33–36 g/dL |
| 379 | Mean corpuscular volume | 80–98 fL |
| 380 | Mean platelet volume | 7–9 fL |
| 381 | Metanephrines, fractionated, plasma | |
| 382 | Metanephrine | <0.5 nmol/L |
| 383 | Normetanephrine | <0.9 nmol/L |
| 384 | Metanephrines, fractionated, 24-hour urine | |
| 385 | Metanephrine | <400 µg/24 hr |
| 386 | Normetanephrine | <900 µg/24 hr |
| 387 | Myoglobin, serum | <100 µg/L |
| 388 | Norepinephrine, plasma | |
| 389 | Supine | 70–750 pg/mL |
| 390 | Standing | 200–1700 pg/mL |
| 391 | Norepinephrine, urine | 0–100 µg/24 hr |
| 392 | Normetanephrine, fractionated, plasma | <0.9 nmol/L |
| 393 | Normetanephrine, fractionated, 24-hour urine | <900 µg/24 hr |
| 394 | <i>N-telopeptide, urine</i> | Female: 11–48 nmol BCE/mmol creatinine; |
| 395 | <i>N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP),</i> | If eGFR >60 mL/min/1.73 m ² 18–49 years |
| 396 | Osmolality, serum | 275–295 mOsm/kg H ₂ O |
| 397 | Osmolality, urine | 38–1400 mOsm/kg H ₂ O |
| 398 | Osmotic fragility of erythrocytes | Increased if hemolysis occurs in over |
| 399 | Osteocalcin, serum | Female: 7.2–27.9 ng/mL; male: 11.3–35.4 |
| 400 | Oxalate, urine | <40 mg/24 hr |
| 401 | Oxygen consumption | 225–275 mL/min |
| 402 | Oxygen saturation, arterial blood | ≥95% |
| 403 | Parathyroid hormone, serum | |
| 404 | <i>C-terminal</i> | 150–350 pg/mL |
| 405 | Intact | 10–65 pg/mL |
| 406 | Intact (dialysis patients only) | Target: 130–585 pg/mL |
| 407 | Parathyroid hormone-related protein, serum | <1.5 pmol/L |
| 408 | Partial thromboplastin time (activated) APTT | 25–35 seconds |
| 409 | pH, urine | 4.5–8.0 |
| 410 | Phenolsulfonphthalein, urine | At least 25% excreted by 15 minutes; 40% |
| 411 | Phenytoin, serum | Therapeutic: 10–20 µg/mL |
| 412 | Phosphatase (acid), serum | |
| 413 | Phosphatase (acid), serum Total | 0.5–2.0 (Bodansky) units/mL |
| 414 | Prostatic fraction | 0.1–0.4 unit/mL |
| 415 | Phosphatase (alkaline), serum | 30–120 U/L |
| 416 | Phospholipids, serum (total) | 200–300 mg/dL |
| 417 | Phosphorus, serum | 3.0–4.5 mg/dL |
| 418 | Phosphorus, urine | 500–1200 mg/24 hr |
| 419 | Platelet count | 150,000–450,000/µL |
| 420 | Platelet function analysis (PFA-100): | |
| 421 | Collagen–epinephrine closure time | 60–143 seconds |

| | | |
|-----|---|--|
| 422 | Collagen-ADP closure time | 58-123 seconds |
| 423 | Platelet survival rate (⁵¹ Cr) | 10 days |
| 424 | Potassium, serum | 3.5-5.0 mEq/L |
| 425 | Potassium, urine | |
| 426 | Spot | mEq/L; varies |
| 427 | 24-hour measurement | mEq/24 hr; varies with intake |
| 428 | Prealbumin, serum | 16-30 mg/dL |
| 429 | Pregnanetriol, urine | 0.2-3.5 mg/24 hr |
| 430 | Pressure (opening) [initial], CSF | 70-180 mm CSF (70-180 mm H ₂ O) |
| 431 | Procalcitonin, serum | ≤0.10 ng/mL |
| 432 | Progesterone, serum | |
| 433 | Progesterone Female, follicular | 0.02-0.9 ng/mL |
| 434 | Progesterone Female, luteal | 2-30 ng/mL |
| 435 | Progesterone Male (adult) | 0.12-0.3 ng/mL |
| 436 | Proinsulin, serum | 3-20 pmol/L |
| 437 | Prolactin, serum | <20 ng/mL |
| 438 | Prostate-specific antigen, serum | ng/mL; no specific normal or abnormal |
| 439 | Protein C activity, plasma | 65%-150% |
| 440 | Protein C antigen, plasma | 70%-140% |
| 441 | Protein catabolic rate, urine | goal: 1.0-1.2 g/kg/24 hr |
| 442 | Protein S activity, plasma | 57%-131% |
| 443 | Protein S antigen, plasma | |
| 444 | Total | 60%-140% |
| 445 | Free | 60%-130% |
| 446 | Protein, urine | |
| 447 | Spot | mg/dL; varies |
| 448 | 24-hour measurement | <100 mg/24 hr |
| 449 | Proteins, CSF total | 15-45 mg/dL |
| 450 | Proteins, serum | |
| 451 | Proteins Total | 5.5-9.0 g/dL |
| 452 | Albumin | 3.5-5.5 g/dL |
| 453 | Proteins, serum (continued) | |
| 454 | Globulin | 2.0-3.5 g/dL |
| 455 | Alpha1 | 0.2-0.4 g/dL |
| 456 | Alpha2 | 0.5-0.9 g/dL |
| 457 | Beta | 0.6-1.1 g/dL |
| 458 | Gamma | 0.7-1.7 g/dL |
| 459 | Protein-to-creatinine ratio, urine | <0.2 mg/mg |
| 460 | Prothrombin time, plasma | 11-13 seconds |
| 461 | Pyruvic acid, blood | 0.08-0.16 mmol/L |
| 462 | Quinidine, serum | Therapeutic: 2-5 µg/mL |
| 463 | Red cell distribution width (RDW) | 9.0-14.5 |
| 464 | Red cell mass | Female: 22.7-27.9 mL/kg; male: 24.9-32.5 |
| 465 | Renin activity (angiotensin-I radioimmunoassay) | |
| 466 | Peripheral plasma | |
| 467 | Normal diet | |
| 468 | Supine | 0.3-2.5 ng/mL/hr |

| | | |
|-----|---|---|
| 469 | Upright | 0.2–3.6 ng/mL/hr |
| 470 | Low sodium diet | |
| 471 | Supine | 0.9–4.5 ng/mL/hr |
| 472 | Upright | 4.1–9.1 ng/mL/hr |
| 473 | Diuretics + low sodium diet | 6.3–13.7 ng/mL/hr |
| 474 | Renal vein concentration | Normal ratio (high:low): <1.5 |
| 475 | Reptilase time | 10–12 seconds |
| 476 | Reticulocyte count | 0.5%–1.5% of red cells |
| 477 | Reticulocyte count, absolute | 25,000–100,000/ μ L |
| 478 | Rheumatoid factor (nephelometry) | <24 IU/mL |
| 479 | Rheumatoid factor, latex test for | \leq 1:80 |
| 480 | Ristocetin cofactor activity of plasma | 50%–150% |
| 481 | Russell viper venom time, dilute | 33–44 seconds |
| 482 | Salicylate, plasma | Therapeutic: 20–30 mg/dL |
| 483 | Sex hormone-binding globulin | Female, nonpregnant: 18–144 |
| 484 | Sodium, serum | 136–145 mEq/L |
| 485 | Sodium, urine | |
| 486 | Spot | mEq/L; varies |
| 487 | 24-hour measurement | mEq/24 hr; varies with intake |
| 488 | Specific gravity, urine | 1.002–1.030 |
| 489 | Sperm density | 10–150 million/mL |
| 490 | Sweat test for sodium and chloride | <60 mEq/L |
| 491 | T3 resin uptake | 25%–35% |
| 492 | T-lymphocyte count, CD4 | 530–1570/ μ L |
| 493 | Tacrolimus, whole blood (trough) | Therapeutic: 5–15 ng/mL {For transplant |
| 494 | Testosterone, serum | Female: 18–54 ng/dL; male: 291–1100 |
| 495 | Testosterone, bioavailable, serum | Female, age 18–69 yrs: 0.5–8.5 ng/dL |
| 496 | Testosterone, free, serum | Male: 70–300 pg/mL |
| 497 | Theophylline, serum | Therapeutic: 8–20 μ g/mL |
| 498 | Thrombin time | 17–23 seconds |
| 499 | Thyroid function studies | |
| 500 | T3 resin uptake | 25%–35% |
| 501 | Thyroglobulin, serum | <20 ng/mL |
| 502 | Thyroidal iodine (¹²³ I) uptake | 5%–30% of administered dose at 24 hours |
| 503 | Thyroid-stimulating hormone (TSH), serum | 0.5–4.0 μ U/mL (0.5–4.0 mU/L) |
| 504 | Thyroid-stimulating immunoglobulin (TSI) | <130% |
| 505 | Thyroxine-binding globulin, serum | 12–27 μ g/mL |
| 506 | Thyroxine index, free (estimate) | 5–12 |
| 507 | Thyroxine (T ₄), serum | |
| 508 | Thyroxine (T ₄) Total | 5–12 μ g/dL |
| 509 | Thyroxine (T ₄) Free FT ₄ | 0.8–1.8 ng/dL |
| 510 | Triiodothyronine (T ₃), serum | |
| 511 | Triiodothyronine (T ₃) Total | 80–180 ng/dL |
| 512 | Triiodothyronine (T ₃) Reverse | 20–40 ng/dL |
| 513 | Triiodothyronine (T ₃) Free FT ₃ | 2.3–4.2 pg/mL |
| 514 | Tissue transglutaminase antibody, IgA[by | <20 AU |
| 515 | Tissue transglutaminase antibody, IgG[by | <20 AU |

| | | |
|-----|---|--|
| 516 | Tissue transglutaminase antibody, IgA[by ELISA] | <4.0 U/mL |
| 517 | Tissue transglutaminase antibody, IgG[by ELISA] | <6.0 U/mL |
| 518 | Total proteins, CSF | 15–45 mg/dL |
| 519 | Transaminase, serum glutamic oxaloacetic (SGOT) | <i>See</i> Aminotransferase, serum aspartate |
| 520 | Transaminase, serum glutamic pyruvic (SGPT) | <i>See</i> Aminotransferase, serum alanine |
| 521 | Transferrin saturation | 20%–50% |
| 522 | Transferrin, serum | 200–400 mg/dL |
| 523 | Triglycerides, serum (fasting) | |
| 524 | Triglycerides Optimal | <100 mg/dL |
| 525 | Triglycerides Normal | <150 mg/dL |
| 526 | Triglycerides Borderline-high | 150–199 mg/dL |
| 527 | Triglycerides High | 200–499 mg/dL |
| 528 | Triglycerides Very high | >499 mg/dL |
| 529 | Troponin I, cardiac, serum | ≤0.04 ng/mL |
| 530 | Troponin T, cardiac, serum | ≤0.01 ng/mL |
| 531 | Tryptase, serum | <11.5 ng/mL |
| 532 | Urea clearance, urine | |
| 533 | Urea clearance Standard | 40–60 mL/min |
| 534 | Urea clearance Maximal | 60–100 mL/min |
| 535 | Urea nitrogen, blood | 8–20 mg/dL |
| 536 | Urea nitrogen, urine | 12–20 g/24 hr |
| 537 | Uric acid, serum | 3.0–7.0 mg/dL |
| 538 | Uric acid, urine | 250–750 mg/24 hr |
| 539 | Uroporphyrin, urine | 10–30 µg/24 hr |
| 540 | Vanillylmandelic acid, urine | <9 mg/24 hr |
| 541 | Venous oxygen content, mixed | 14–16 mL/dL |
| 542 | Zinc | 70 - 150 mg/dl |